Ghebremariam
Teklegiorgis Ghebremariam, Los Angeles, CA US
Patent application number | Description | Published |
---|---|---|
20130108642 | IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH | 05-02-2013 |
Yohannes T. Ghebremariam, Stanta Clara, CA US
Patent application number | Description | Published |
---|---|---|
20120208232 | Cell-Free Synthesis of Active Reprogramming Transcription Factors - Compositions and methods are provided for the cell-free synthesis of active reprogramming factor polypeptides. The reprogramming factors may be synthesized as fusion proteins comprising a permeant domain, such as polyarginme. The cell free-synthesis may be conducted at about 25 C in a bacterial cell extract from genetically alterd cells having decreased endogenous protease activity Further, the proteins may comprise a fusion partner which enhances solubility and may be refolded on a column. | 08-16-2012 |
Yohannes T. Ghebremariam, Santa Clara, CA US
Patent application number | Description | Published |
---|---|---|
20130224259 | Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof - The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X. | 08-29-2013 |
Yohannes T. Ghebremariam, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20150238472 | Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof - The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X. | 08-27-2015 |
Yohannes Tsegai Ghebremariam, Stanford, CA US
Patent application number | Description | Published |
---|---|---|
20080318858 | Isolated Recombinant Vaccinia Virus Complement Control Protein (Hrvcp) Polypeptide - An isolated recombinant vaccinia virus complement control protein (hrVCP) polypeptide comprises a modified amino acid sequence comprising one or more amino acid substitutions to an amino acid sequence as set forth in SEQ ID NO: 2. The hrVCP polypeptide exhibits a complement activation regulatory activity greater than a complement activation regulatory activity of a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2. The one or more amino acid substitutions are selected from the group consisting of H98Y, E102K, E108K, E120K, and combinations thereof. | 12-25-2008 |